Skip to main content
PMC home page
The Journal of Cell Biology logoLink to The Journal of Cell Biology
. 1989 May 1;108(5):1987–1995. doi: 10.1083/jcb.108.5.1987

Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants

PMCID: PMC2115548  PMID: 2523891

Abstract

Human HT-1080 fibrosarcoma cells produce urokinase-type plasminogen activator (u-PA) and type 1 plasminogen activator inhibitor (PAI-1). We found that after incubation of monolayer cultures with purified native human plasminogen in serum-containing medium, bound plasmin activity could be eluted from the cells with tranexamic acid, an analogue of lysine. The bound plasmin was the result of plasminogen activation on the cell surface; plasmin activity was not taken up onto cells after deliberate addition of plasmin to the serum-containing medium. The cell surface plasmin formation was inhibited by an anticatalytic monoclonal antibody to u-PA, indicating that this enzyme was responsible for the activation. Preincubation of the cells with diisopropyl fluorophosphate- inhibited u-PA led to a decrease in surface-bound plasmin, indicating that a large part, if not all, of the cell surface plasminogen activation was catalyzed by surface-bound u-PA. In the absence of plasminogen, most of the cell surface u-PA was present in its single- chain proenzyme form, while addition of plasminogen led to formation of cell-bound two-chain u-PA. The latter reaction was catalyzed by cell- bound plasmin. Cell-bound u-PA was accessible to inhibition by endogenous PAI-1 and by added PAI-2, while the cell-bound plasmin was inaccessible to serum inhibitors, but accessible to added aprotinin and an anticatalytic monoclonal antibody. A model for cell surface plasminogen activation is proposed in which plasminogen binding to cells from serum medium is followed by plasminogen activation by trace amounts of bound active u-PA, to form bound plasmin, which in turn serves to produce more active u-PA from bound pro-u-PA. This exponential process is subject to regulation by endogenous PAI-1 and limited to the pericellular space.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Nielsen L. S., Kristensen P., Grøndahl-Hansen J., Skriver L., Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem. 1986 Jun 15;261(17):7644–7651. [PubMed] [Google Scholar]
  2. Bergman B. L., Scott R. W., Bajpai A., Watts S., Baker J. B. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci U S A. 1986 Feb;83(4):996–1000. doi: 10.1073/pnas.83.4.996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blasi F., Vassalli J. D., Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987 Apr;104(4):801–804. doi: 10.1083/jcb.104.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  5. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  6. Danø K., Reich E. Plasminogen activator from cells transformed by an oncogenic virus: inhibitors of the activation reaction. Biochim Biophys Acta. 1979 Jan 12;566(1):138–151. doi: 10.1016/0005-2744(79)90256-0. [DOI] [PubMed] [Google Scholar]
  7. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  8. Ellis V., Scully M. F., Kakkar V. V. Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. J Biol Chem. 1987 Nov 5;262(31):14998–15003. [PubMed] [Google Scholar]
  9. Golder J. P., Stephens R. W. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem. 1983 Nov 15;136(3):517–522. doi: 10.1111/j.1432-1033.1983.tb07771.x. [DOI] [PubMed] [Google Scholar]
  10. Green G. D., Shaw E. Thiobenzyl benzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. Anal Biochem. 1979 Mar;93(2):223–226. doi: 10.1016/s0003-2697(79)80141-4. [DOI] [PubMed] [Google Scholar]
  11. Hajjar K. A., Harpel P. C., Jaffe E. A., Nachman R. L. Binding of plasminogen to cultured human endothelial cells. J Biol Chem. 1986 Sep 5;261(25):11656–11662. [PubMed] [Google Scholar]
  12. Hearing V. J., Law L. W., Corti A., Appella E., Blasi F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 1988 Mar 1;48(5):1270–1278. [PubMed] [Google Scholar]
  13. Hekman C. M., Loskutoff D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581–11587. [PubMed] [Google Scholar]
  14. Hynes R. O. Integrins: a family of cell surface receptors. Cell. 1987 Feb 27;48(4):549–554. doi: 10.1016/0092-8674(87)90233-9. [DOI] [PubMed] [Google Scholar]
  15. Hébert C. A., Baker J. B. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol. 1988 Apr;106(4):1241–1247. doi: 10.1083/jcb.106.4.1241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  17. Laiho M., Saksela O., Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem. 1987 Dec 25;262(36):17467–17474. [PubMed] [Google Scholar]
  18. Leung K. C., Byatt J. A., Stephens R. W. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin). Thromb Res. 1987 Jun 15;46(6):755–766. doi: 10.1016/0049-3848(87)90068-5. [DOI] [PubMed] [Google Scholar]
  19. Liotta L. A., Goldfarb R. H., Brundage R., Siegal G. P., Terranova V., Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981 Nov;41(11 Pt 1):4629–4636. [PubMed] [Google Scholar]
  20. MacGregor I. R., Micklem L. R., James K., Pepper D. S. Characterisation of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies. Thromb Haemost. 1985 Feb 18;53(1):45–50. [PubMed] [Google Scholar]
  21. Mignatti P., Robbins E., Rifkin D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986 Nov 21;47(4):487–498. doi: 10.1016/0092-8674(86)90613-6. [DOI] [PubMed] [Google Scholar]
  22. Miles L. A., Plow E. F. Binding and activation of plasminogen on the platelet surface. J Biol Chem. 1985 Apr 10;260(7):4303–4311. [PubMed] [Google Scholar]
  23. Mimuro J., Schleef R. R., Loskutoff D. J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood. 1987 Sep;70(3):721–728. [PubMed] [Google Scholar]
  24. Nielsen L. S., Andreasen P. A., Grøndahl-Hansen J., Huang J. Y., Kristensen P., Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification. Thromb Haemost. 1986 Apr 30;55(2):206–212. [PubMed] [Google Scholar]
  25. Nielsen L. S., Grøndahl-Hansen J., Andreasen P. A., Skriver L., Zeuthen J., Danø K. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay. 1986;7(3):209–228. doi: 10.1080/01971528608060467. [DOI] [PubMed] [Google Scholar]
  26. Nielsen L. S., Hansen J. G., Skriver L., Wilson E. L., Kaltoft K., Zeuthen J., Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry. 1982 Dec 7;21(25):6410–6415. doi: 10.1021/bi00268a014. [DOI] [PubMed] [Google Scholar]
  27. Nielsen L. S., Kellerman G. M., Behrendt N., Picone R., Danø K., Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem. 1988 Feb 15;263(5):2358–2363. [PubMed] [Google Scholar]
  28. O'Grady R. L., Upfold L. I., Stephens R. W. Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. Int J Cancer. 1981 Oct 15;28(4):509–515. doi: 10.1002/ijc.2910280418. [DOI] [PubMed] [Google Scholar]
  29. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell. 1988 Feb 12;52(3):321–328. doi: 10.1016/s0092-8674(88)80025-4. [DOI] [PubMed] [Google Scholar]
  30. Petersen L. C., Lund L. R., Nielsen L. S., Danø K., Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem. 1988 Aug 15;263(23):11189–11195. [PubMed] [Google Scholar]
  31. Plow E. F., Freaney D. E., Plescia J., Miles L. A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol. 1986 Dec;103(6 Pt 1):2411–2420. doi: 10.1083/jcb.103.6.2411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pöllänen J., Hedman K., Nielsen L. S., Danø K., Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol. 1988 Jan;106(1):87–95. doi: 10.1083/jcb.106.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pöllänen J., Saksela O., Salonen E. M., Andreasen P., Nielsen L., Danø K., Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987 Apr;104(4):1085–1096. doi: 10.1083/jcb.104.4.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Saksela O., Vaheri A., Schleuning W. D., Mignatti P., Barlati S. Plasminogen activators, activation inhibitors and alpha 2-macroglobulin produced by cultured normal and malignant human cells. Int J Cancer. 1984 May 15;33(5):609–616. doi: 10.1002/ijc.2910330510. [DOI] [PubMed] [Google Scholar]
  35. Salonen E. M., Tervo T., Törmä E., Tarkkanen A., Vaheri A. Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy. Acta Ophthalmol (Copenh) 1987 Feb;65(1):3–12. doi: 10.1111/j.1755-3768.1987.tb08482.x. [DOI] [PubMed] [Google Scholar]
  36. Sim P. S., Fayle D. R., Doe W. F., Stephens R. W. Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator. Eur J Biochem. 1986 Aug 1;158(3):537–542. doi: 10.1111/j.1432-1033.1986.tb09787.x. [DOI] [PubMed] [Google Scholar]
  37. Stephens R. W., Fordham C. J., Doe W. F. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation. Eur J Cancer Clin Oncol. 1987 Feb;23(2):213–222. doi: 10.1016/0277-5379(87)90017-4. [DOI] [PubMed] [Google Scholar]
  38. Stephens R. W., Golder J. P., Fayle D. R., Hume D. A., Hapel A. J., Allan W., Fordham C. J., Doe W. F. Minactivin expression in human monocyte and macrophage populations. Blood. 1985 Aug;66(2):333–337. [PubMed] [Google Scholar]
  39. Stephens R., Alitalo R., Tapiovaara H., Vaheri A. Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors. Leuk Res. 1988;12(5):419–422. doi: 10.1016/0145-2126(88)90061-6. [DOI] [PubMed] [Google Scholar]
  40. Stephens R., Leung K. C., Pöllänen J., Salonen E. M., Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods. 1987 Dec 24;105(2):245–251. doi: 10.1016/0022-1759(87)90272-9. [DOI] [PubMed] [Google Scholar]
  41. Stoppelli M. P., Corti A., Soffientini A., Cassani G., Blasi F., Assoian R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939–4943. doi: 10.1073/pnas.82.15.4939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stoppelli M. P., Tacchetti C., Cubellis M. V., Corti A., Hearing V. J., Cassani G., Appella E., Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell. 1986 Jun 6;45(5):675–684. doi: 10.1016/0092-8674(86)90782-8. [DOI] [PubMed] [Google Scholar]
  43. Sullivan L. M., Quigley J. P. An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts. Cell. 1986 Jun 20;45(6):905–915. doi: 10.1016/0092-8674(86)90565-9. [DOI] [PubMed] [Google Scholar]
  44. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  45. Tryggvason K., Höyhtyä M., Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987 Nov 25;907(3):191–217. doi: 10.1016/0304-419x(87)90006-0. [DOI] [PubMed] [Google Scholar]
  46. Vassalli J. D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86–92. doi: 10.1083/jcb.100.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Werb Z., Mainardi C. L., Vater C. A., Harris E. D., Jr Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med. 1977 May 5;296(18):1017–1023. doi: 10.1056/NEJM197705052961801. [DOI] [PubMed] [Google Scholar]
  48. Wun T. C., Reich E. An inhibitor of plasminogen activation from human placenta. Purification and characterization. J Biol Chem. 1987 Mar 15;262(8):3646–3653. [PubMed] [Google Scholar]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press

RESOURCES